翻訳と辞書 |
Sacituzumab govitecan : ウィキペディア英語版 | Sacituzumab govitecan Sacituzumab govitecan (previously IMMU-132) is an antibody-drug conjugate being investigated as a treatment for cancers such as pancreatic cancers, small-cell lung cancer(SCLC) and triple-negative breast cancer.〔(FDA Fast Track for TNBC )〕 It is a conjugate of the humanized anti-Trop-2 monoclonal antibody (hRS7) with SN-38, the active metabolite of irinotecan.〔(Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. 2015 )〕 Encouraging results have been reported in a phase II trial for metastatic gastrointestinal cancers.〔(P-162 Interim Results of IMMU-132 (Sacituzumab Govitecan), an Anti-Trop-2 Antibody-Drug Conjugate (ADC), in Patients (pts) with Metastatic Gastrointestinal (GI) Cancers )〕 Encouraging results have been reported in a phase II trial for metastatic TNBC.〔(Immunomedics Reports Complete Responses in Patients With Metastatic Triple-Negative Breast Cancer After Sacituzumab Govitecan Treatment )〕 ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Sacituzumab govitecan」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|